Theranos Fraud: Theranos: How False Claims, Weak Governance and Failed Technology Led to Criminal Convictions

Q: How much money did Theranos raise?

Theranos raised over $700 million from investors including Rupert Murdoch, Larry Ellison, the Walton family, and others. At its peak, the company was valued at $9 billion.

Q: What happened to Elizabeth Holmes?

Holmes was indicted for fraud in 2018, convicted in January 2022, and sentenced in November 2022 to 11 years and 3 months (135 months) in prison. She is serving her sentence at FPC Bryan, Texas. Her conviction was upheld on appeal in 2025; with good-conduct reductions her projected release date is August 2032.

Q: Why did investors believe Theranos?

Investors were influenced by Holmes's compelling narrative, the prestigious board (Kissinger, Shultz, Mattis), and the fear of missing out on the next Steve Jobs. Most investors did not conduct independent technical verification of the core technology claims.

Q: What lessons can boards learn from Theranos?

Key lessons: (1) Boards must include domain experts who can validate technical claims, (2) Due diligence must include independent testing, (3) Whistleblower channels must be protected, (4) Charismatic founders should not be immune to scrutiny, and (5) Governance must verify, not just endorse.

Q: Who exposed the Theranos fraud?

The fraud was exposed by investigative journalist John Carreyrou of The Wall Street Journal, published in October 2015. Whistleblowers including Tyler Shultz and Erika Cheung provided crucial evidence.

Ramesh Dixit

Investigation PIA-INV-006Corporate DisastersCost: $700M4 min read

Theranos Fraud

Theranos: How False Claims, Weak Governance and Failed Technology Led to Criminal Convictions

Filed under: The Business Behind Megaprojects · Theranos · United States · Healthcare & Health IT

Written and edited by Ramesh Dixit·Published 2026-07-06·Last updated 2026-07-06·Last fact-checked 2 August 2026·Editorial Standards · Editorial Policy · Corrections Policy · Methodology · Source Standards · AI Disclosure

Download Executive Brief (PDF)

Theranos raised hundreds of millions of dollars while its blood-testing technology failed to perform as publicly represented. This investigation reveals how a governance structure designed to impress rather than oversee allowed one of the largest frauds in Silicon Valley history to unfold.

Theranos Fraud — investigative documentary thumbnail

Key Facts

Cost

$700M

Date

2026-07-06

What Happened

Theranos was a blood-testing company founded by Elizabeth Holmes in 2003. The company claimed its technology could run comprehensive blood tests from a single finger-prick of blood. Holmes raised over $700 million from investors including Rupert Murdoch, Larry Ellison, and the Walton family. The board included Henry Kissinger, George Shultz, and Jim Mattis. However, the technology never worked as claimed. In 2015, Wall Street Journal reporting in 2015 exposed major discrepancies between Theranos's public claims and the performance of its technology. Subsequent regulatory action and criminal proceedings established fraudulent conduct. Holmes was indicted in 2018, convicted of fraud in January 2022, and sentenced in November 2022 to 11 years and 3 months (135 months) in prison.

Why It Matters

Theranos extracted $700 million from sophisticated investors not through technological deception alone, but through a governance structure that made verification impossible. According to trial testimony and Wall Street Journal reporting, Holmes tightly restricted information flow between the lab and the board, ensuring that Henry Kissinger and George Shultz — eminent statesmen with zero medical expertise — could only repeat what they were told. Tyler Shultz, grandson of board member George Shultz, became a whistleblower precisely because internal channels were blocked. For Asia's venture capital ecosystem — where due diligence cycles are often compressed and founder narratives carry disproportionate weight — Theranos demonstrates that technical validation must be conducted by independent domain experts with direct lab access, not delegated to advisory boards chosen for their networking value. The Leadership Blind Spot Matrix™ exposes the four hidden governance patterns that make fraud structurally inevitable.

Timeline

proposal 2003
Elizabeth Holmes founds Theranos (initially 'Real-Time Cures') after dropping out of Stanford.
approval 2010
Theranos begins partnership negotiations with Walgreens for in-store blood-testing 'wellness centers'.
warning 2013-09
Theranos begins rolling out Walgreens wellness centers (Palo Alto pilot, then ~40 Arizona stores) without independent validation of its proprietary devices.
warning 2015-10-16
Wall Street Journal publishes John Carreyrou's exposé reporting that Theranos ran most tests on conventional machines and diluted samples, not its Edison devices.
failure 2016-01-25
CMS letter to Theranos declares the Newark lab's deficient practices pose 'immediate jeopardy to patient health and safety' after a CLIA survey.
failure 2016-03-18
CMS notifies Theranos of proposed sanctions including revocation of its CLIA certificate and a two-year ban on Holmes, Balwani and the lab director.
failure 2016-05-18
Theranos voids two years of Edison test results, issuing tens of thousands of corrected reports to doctors and patients.
failure 2016-06-12
Walgreens terminates its Theranos partnership for cause and closes all wellness centers.
settlement 2016-07-07
CMS imposes final sanctions: revocation of the Newark lab's CLIA certificate, civil money penalty, and Medicare payment cancellation.
settlement 2018-03-14
SEC charges Theranos, Holmes and Balwani with raising over $700 million through an 'elaborate, years-long fraud'; Holmes settles with a $500,000 penalty and 10-year officer/director bar.
inquiry 2018-06-15
Federal grand jury indictment of Holmes and Balwani is unsealed (two conspiracy counts, nine wire fraud counts); Holmes steps down as CEO.
scrapped 2018-09
Theranos announces it will dissolve, ending the company.
conviction 2022-01-03
Holmes is convicted by a jury on four counts of investor fraud and conspiracy.
conviction 2022-07
Balwani is convicted on twelve counts of wire fraud and conspiracy, including patient-facing fraud; Holmes is later sentenced to 135 months (Nov 2022) and Balwani to nearly 13 years (Dec 2022).

Root Cause Analysis

Root cause through the Leadership Blind Spot Matrix™ lens

Pattern Overconfidence

Over-reliance on past experience in novel situations

Dissent Filtering

Systematic exclusion of challenging perspectives

Risk Discounting

Underestimating emerging threats due to present-focus

Attribution Errors

Misattributing success to skill rather than context

Frameworks Applied

Framework Applied

Leadership Blind Spot Matrix™

Identifying What Leaders Cannot See — explore the framework →

Framework Applied

Project Failure Pyramid™

The 4-Level Diagnostic for Cascading Failures — explore the framework →

Executive Lessons

Lessons for Leaders

Board Composition Must Include Technical Validators

Theranos's board included Henry Kissinger, George Shultz, and Jim Mattis — eminent statesmen with zero medical expertise. When a board lacks domain-specific technical knowledge, it cannot validate claims or spot fraud. Reputation is not a substitute for expertise.

Due Diligence Must Include Independent Testing

Major investors including Walgreens and Safeway conducted limited due diligence that did not include independent verification of the core technology claim. When you invest in a technology company, test the technology independently before you invest.

Whistleblowers Need Protected Channels

Tyler Shultz, grandson of board member George Shultz, became a whistleblower because internal channels were blocked. When employees cannot raise concerns internally, they raise them publicly — or not at all. Protected whistleblower channels are governance infrastructure.

Executive Recommendations

Include independent technical validators on boards of science-based ventures.

Require independent third-party testing as a non-negotiable condition of due diligence.

Establish protected whistleblower channels; legal intimidation of dissent is a fraud signal, not a defence.

Treat secrecy that prevents internal integration of information as a governance risk in itself.

Continue Investigating

Billion Dollar Failures$560M delay costs (system ~$200M)

Denver Airport Baggage System

4 min read

GovernanceUS$327.6 million (total mission cost, per NASA)

Mars Climate Orbiter

17 min read

The Weekly Brief — one investigation, one executive lesson and one project warning sign each week.

Subscribe free

PMOS Intelligence

Preview — illustrative assessment; PMOS is in development

Governance WeaknessThe board was composed to impress — Kissinger, Shultz, Mattis — rather than to oversee, with no member capable of technically validating the core blood-testing claim.

Escalation FailureInternal whistleblowers had no protected channel and were met with legal intimidation, so the truth escaped only through Wall Street Journal reporting in 2015.

Decision DelayInvestors and partners committed hundreds of millions over more than a decade without ever requiring an independent demonstration that the technology worked.

Leadership Blind SpotLeadership substituted narrative, secrecy and boardroom prestige for evidence, treating validation requests as disloyalty rather than diligence.

Risk VisibilityCompartmentalised teams and secrecy meant no single internal group — let alone the board — could see the whole picture of what the technology could not do.

Evidence QualityFalsifying evidence was the failure mechanism: demonstrations were staged and results were run on third-party machines, so the 'evidence' investors saw was manufactured.

Assurance MaturityThere was effectively no assurance function: no independent technical validation, no audited performance data, and no due-diligence regime among sophisticated investors.

Suggested InterventionAn independent PMO or technical assurance function would have required blinded third-party validation of test accuracy before any capital raise, partnership or patient deployment — and would have protected internal dissent channels from day one.

“Theranos extracted $700 million from sophisticated investors not through technological deception alone, but through a governance structure that made verification impossible. According to trial testimony and Wall Street Journal reporting, Holmes tightly restricted information flow between the lab and the board, ensuring that eminent statesmen could only repeat what they were told. Tyler Shultz, grandson of board member George Shultz, became a whistleblower precisely because internal channels were blocked. For Asia's venture capital ecosystem — where due diligence cycles are often compressed and founder narratives carry disproportionate weight — Theranos demonstrates that technical validation must be conducted by independent domain experts with direct lab access, not delegated to advisory boards chosen for their networking value.”Ramesh's Insider Take — opinion

Evidence

Documentary Evidence

regulatory enforcement complaint

SEC complaint, SEC v. Elizabeth Holmes and Theranos, Inc. (N.D. Cal., filed March 14, 2018)

U.S. Securities and Exchange Commission · 2018-03-14

The complaint establishes the SEC's case that Theranos raised more than $700 million through false claims about its blood-testing technology, pharmaceutical and military validation, and financial performance — the core of the governance and disclosure failure.

View document →

regulatory sanctions correspondence / congressional oversight

CMS letters to Theranos (Jan 25 and Mar 18, 2016), as documented in House Energy & Commerce oversight letter

CMS / U.S. House Energy and Commerce Committee · 2016

Documents the 'immediate jeopardy' finding against Theranos's Newark laboratory, the rejection of its corrective plans, and the resulting CLIA sanctions — the regulatory failure at the heart of the patient-safety dimension.

View document →

prosecutorial official statement

DOJ press release on Holmes sentencing (U.S. v. Holmes, N.D. Cal.)

U.S. Department of Justice, USAO NDCA · 2022-11-18

Official DOJ account of the 135-month sentence, confirming the jury conviction on investor-fraud counts and restitution — the judicial endpoint of the fraud.

View document →

investigative journalism (primary exposé)

Wall Street Journal: 'Hot Startup Theranos Has Struggled With Its Blood-Test Technology' (John Carreyrou)

The Wall Street Journal · 2015-10-16

The first public exposé establishing that Theranos performed only a small fraction of tests on its proprietary Edison devices and allegedly diluted samples for proficiency tests — the trigger for regulatory investigations.

View document →

professional-journalism analysis of court records

AHCJ summary of the June 2018 federal indictment of Holmes and Balwani

Association of Health Care Journalists · 2018-06

Documents the indictment's structure (two conspiracy counts, nine wire-fraud counts, scheme to defraud investors, doctors and patients) and confirms it grew out of a 30-month investigation sparked by the WSJ reporting.

View document →

Asset Hub